Intra-Cellular Therapies (ITCI): Previewing Phase III 302 of ITI-007 In Schizophrenia - Piper Jaffray
Tweet Send to a Friend
Piper Jaffray analyst, Charles Duncan, previewed results from on Intra-Cellular Therapies' (NASDAQ: ITCI) second Phase III “302” trial of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
